Market Report

Antibody Drug Conjugates Market Report 2026-2036

The global Antibody Drug Conjugates market is projected to grow at a CAGR of 11.8% by 2036

SKU: PHA1396 Category: Code: PHA1396Pages: 431
Clear
← Back to category Drug Discovery Development & Production

Description

Visiongain has published a new report, Antibody Drug Conjugates Market Report 2026-2036, providing a comprehensive analysis of the global ADC market, including market size, growth drivers, competitive positioning, and revenue forecasts across product, payload type, linker type, target antigen, application, and end-user segments.

The global ADC market is valued at US$18.42 billion in 2026 and is forecast to reach US$55.94 billion by 2036, at a CAGR of 11.8% over the forecast period, driven by the rising global cancer burden, accelerating R&D investment, novel target diversification beyond HER2, and expanding clinical adoption of ADC combination therapies.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

 

Technological Innovation Driving Market Expansion

The ADC field is advancing rapidly across antibody engineering, linker chemistry, payload optimisation, and conjugation technologies, supporting development of increasingly differentiated next-generation candidates. Pipeline activity is expanding beyond established targets such as HER2 to include HER3, B7-H3, B7-H4, CLDN18.2, ROR1, and others, with bispecific ADCs targeting combinations such as EGFR/HER3 and CD3/CD7 progressing as approaches to tumour heterogeneity and treatment resistance.

Site-specific conjugation methods including THIOMAB, pClick, and AJICAP attach cytotoxic payloads at fixed antibody positions, giving more uniform drug-to-antibody ratios and reducing aggregation and off-target toxicity versus older random conjugation methods. Linker technology is advancing to remain stable during systemic circulation while enabling controlled payload release within tumour cells, with cleavable linkers responding to tumour-associated enzymes, acidic conditions, or intracellular reducing environments.

Innovation is also expanding beyond traditional tubulin inhibitors toward topoisomerase I inhibitors and novel payload classes, while biparatopic and bispecific ADC designs are improving tumour uptake and addressing uneven antigen expression. On 22 June 2026, Lonza and InduPro announced a licensing agreement combining InduPro’s bispecific antibody capabilities with Lonza’s GlycoConnect, HydraSpace, and linker-payload technologies for next-generation ADC development.

Trade & Supply Chain Dynamics

  • U.S. trade tariffs could place additional cost pressure on ADC companies sourcing specialised chemicals, linker-payload materials, manufacturing equipment, and other inputs through international supply chains.
  • The BIOSECURE Act and related U.S. biosecurity policy measures are increasing scrutiny around certain China-linked biotechnology service providers and supply chains, affecting ADC companies with outsourced antibody production, linker-payload synthesis, conjugation, and analytical testing relationships.
  • Chinese assets made up approximately US$11 billion, or 91%, of the US$12.1 billion in disclosed ADC licensing value in the first half of 2026, making continued access to Chinese ADC innovation commercially significant even as companies navigate biosecurity compliance.
  • Companies are responding by qualifying alternative CDMOs and technology partners in the U.S., Europe, and South Korea, though such transitions can increase technology-transfer requirements, validation costs, and development timelines.
  • Tariffs and biosecurity measures are more likely to reshape sourcing, manufacturing, and partnership strategies than reduce global ADC demand, which remains primarily driven by clinical need and treatment outcomes.

Commercial Impact

  • Supply chain diversification: Companies with significant exposure to affected China-linked suppliers are investing in qualifying alternative CDMOs and building regional manufacturing capability to reduce biosecurity and tariff risk
  • Licensing strategy complexity: The commercial importance of Chinese ADC innovation means companies must balance supply-chain and regulatory risk against continued access to a significant share of global ADC pipeline assets and licensing value
  • Capital concentration: Sustained investor interest in differentiated ADC platforms is supporting progression from discovery into clinical development, with large financing rounds completed by specialist developers in 2025 and 2026
  • Competitive positioning: Companies with site-specific conjugation capability, diversified payload platforms, and regionally resilient manufacturing are best positioned to compete across an expanding multi-target, multi-indication ADC landscape

Company Intelligence

The global ADC market is characterised by large pharmaceutical companies defending established franchises, specialist ADC developers advancing differentiated platforms, and a growing cohort of Chinese biotechnology companies contributing both innovation assets and development services.

Leading companies including Daiichi Sankyo, AstraZeneca, F. Hoffmann-La Roche, Gilead Sciences, and Pfizer are strengthening positions through next-generation ADC programme development, combination therapy approvals, and licensing of differentiated platforms.

Competition is increasingly defined by:

  • Next-generation conjugation platform capability including site-specific and bispecific ADC approaches
  • Novel target antigen breadth beyond HER2 across solid tumour and haematological indications
  • ADC combination therapy development with checkpoint inhibitors and targeted therapies
  • Regionally diversified CDMO and manufacturing relationships to manage biosecurity and tariff risk

This report analyses how competitive positioning is evolving across 20 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected size of the global ADC market by 2036?
  • Which product segments, payload types, and target antigens will drive the fastest growth?
  • How will next-generation conjugation, linker, and payload technologies reshape the competitive landscape?
  • What is the impact of U.S. trade tariffs and biosecurity policy on ADC sourcing, manufacturing, and licensing?
  • How are ADC combination therapies expanding clinical applications and market opportunity?
  • Who are the leading companies and how will their competitive positions evolve?

Report Scope and Data Coverage

  • Global ADC market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across product, payload type, linker type, target antigen, application, and end user
  • Regional and national market forecasts across five regions and 13 leading national markets
  • Competitive intelligence on 20 leading companies

Includes both quantitative forecasting and qualitative strategic analysis covering technology, competition, policy, and supply chain dynamics.

CTA

Segmentation Framework

By Product

  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others (Elahere, Tivdak, Zynlonta, Blenrep, Mylotarg)

By Payload Type

  • Auristatins
  • Maytansinoids
  • Calicheamicin Derivatives
  • Topoisomerase I Inhibitors
  • Pyrrolobenzodiazepine (PBD) Dimers
  • Other Payload Type (Duocarmycin, Amanitins, Others)

By Linker Type

  • Cleavable Linkers
  • Non-Cleavable Linkers

By Target Antigen

  • CD30
  • HER2
  • CD22
  • CD33
  • Other Target Antigens (TROP2, Nectin-4, FRa, HER-3, B7-H3)

By Application

  • Blood Cancer
  • Breast Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Other Applications (Lung, Gastric, Urothelial, Ovarian, Colorectal, Others)

By End User

  • Hospitals & Clinics
  • Speciality Centres
  • Others (Academic Institutions, Research Organisations, Clinical Trial Centres)

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Antibody Drug Conjugates Market Report 2026-2036
Need industry data? Please contact us today.

Company Intelligence Coverage

This report includes detailed profiles of 20 leading companies, including:

  • Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company, Limited
  • AstraZeneca
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ADC Therapeutics SA
  • The Servier Laboratories
  • BioNTech
  • Novartis AG
  • Johnson & Johnson
  • BeOne Medicines
  • Zymeworks Inc.
  • Innovent
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • GSK plc
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • Duality Biologics
  • Merck & Co., Inc.

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and CDMO sourcing intelligence
  • Scenario modelling including tariffs and biosecurity risk

Speak to our team about bespoke requirements

Why This Market Intelligence Matters

  • The ADC market is moving from a concentrated, established-product landscape into a broad, multi-target commercial environment where next-generation platform innovation, combination strategies, and supply-chain resilience are the primary sources of competitive differentiation.
  • Companies and investors that understand these dynamics will be better positioned to evaluate opportunities across the ADC value chain and navigate the evolving trade and biosecurity landscape.
  • Purchase the Antibody Drug Conjugates Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Access the Full Forecast and Competitive Analysis

Purchase the Antibody Drug Conjugates Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Download sample or contact us for enterprise access

 

For enterprise licensing, customised segmentation or analyst briefings, contact Visiongain directly at contactus@visiongain.com

Government Registration
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antibody Drug Conjugates Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Growing Burden of Cancer
3.3.1.2 Presence of Strong Pipeline Drugs in Phase III
3.3.1.3 Increasing Breast Cancer Cases Driving Demand for Antibody-Drug Conjugates
3.3.1.4 Increasing R&D Activities for Development of Novel Therapeutics
3.3.1.5 Emerging Applications Beyond Oncology Expanding the Addressable Market
3.3.2 Market Restraining Factors
3.3.2.1 Complexities in Manufacturing
3.3.2.2 Co-ordination Between Various Biopharmaceutical and CDMOs
3.3.2.3 Antibody and Linker-Related Cytotoxin and Formulation Challenges
3.3.2.4 Adverse Effects of Antibody-Drug Conjugates
3.3.3 Market Opportunities
3.3.3.1 Adoption of Combination Therapies
3.3.3.2 Advancements in Antibody-Drug Conjugates (ADCs)
3.3.3.3 Expanding Industry Investments and Collaborations in ADC Development
3.3.3.4 Emerging Targets
3.4 U.S. Tariffs: What’s the Impact on Global Antibody Drug Conjugates Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L-Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.7 Impact of U.S. and China Trade War on Antibody Drug Conjugates Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST
3.6.1 Political
3.6.2 Economical
3.6.3 Social
3.6.4 Technological
3.7 ADC at Crossroads of Innovation, China-Deals and Policy Shift
3.8 Strategic Acquisitions Driving ADC Portfolio Growth
3.9 Impact of Patent Expiry and Biosimilars on ADC Market
3.10 Pricing and Reimbursement Landscape

4 Antibody Drug Conjugates Market Analysis by Product
4.1 Key Findings
4.2 Product Segment: Market Attractiveness Index
4.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Product
4.4 Kadcyla
4.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 Enhertu
4.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.6 Adcetris
4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 Padcev
4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.7.2 Market Share by Region, 2026 & 2036 (%)
4.8 Trodelvy
4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.8.2 Market Share by Region, 2026 & 2036 (%)
4.9 Polivy
4.9.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.9.2 Market Share by Region, 2026 & 2036 (%)
4.10 Others (Elahere, Tivdak, Zynlonta, Blenrep, Mylotarg)
4.10.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.10.2 Market Share by Region, 2026 & 2036 (%)

5 Antibody Drug Conjugates Market Analysis by Payload Type
5.1 Key Findings
5.2 Payload Type Segment: Market Attractiveness Index
5.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
5.4 Auristatins
5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Maytansinoids
5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Calicheamicin Derivatives
5.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.6.2 Market Share by Region, 2026 & 2036 (%)
5.7 Topoisomerase I Inhibitors
5.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.7.2 Market Share by Region, 2026 & 2036 (%)
5.8 Pyrrolobenzodiazepine (PBD) Dimers
5.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.8.2 Market Share by Region, 2026 & 2036 (%)
5.9 Other Payload Type (Duocarmycin, Amanitins, Others)
5.9.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.9.2 Market Share by Region, 2026 & 2036 (%)

6 Antibody Drug Conjugates Market Analysis by Linker Type
6.1 Key Findings
6.2 Linker Type Segment: Market Attractiveness Index
6.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
6.4 Cleavable Linkers
6.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Non-Cleavable Linkers
6.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Antibody Drug Conjugates Market Analysis by Target Antigen
7.1 Key Findings
7.2 Target Antigen Segment: Market Attractiveness Index
7.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
7.4 CD30
7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 HER2
7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 CD22
7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.6.2 Market Share by Region, 2026 & 2036 (%)
7.7 CD33
7.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.7.2 Market Share by Region, 2026 & 2036 (%)
7.8 Other Target Antigens (TROP2, Nectin-4, FRα, HER-3, B7-H3)
7.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.8.2 Market Share by Region, 2026 & 2036 (%)

8 Antibody Drug Conjugates Market Analysis by Applications
8.1 Key Findings
8.2 Applications Segment: Market Attractiveness Index
8.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
8.4 Blood Cancer
8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Breast Cancer
8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Autoimmune Diseases
8.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.6.2 Market Share by Region, 2026 & 2036 (%)
8.7 Infectious Diseases
8.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.7.2 Market Share by Region, 2026 & 2036 (%)
8.8 Other Applications (Lung, Gastric, Urothelial, Ovarian, Colorectal, Others)
8.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.8.2 Market Share by Region, 2026 & 2036 (%)

9 Antibody Drug Conjugates Market Analysis by End-users
9.1 Key Findings
9.2 End-users Segment: Market Attractiveness Index
9.3 Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
9.4 Hospitals & Clinics
9.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
9.4.2 Market Share by Region, 2026 & 2036 (%)
9.5 Speciality Centres
9.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
9.5.2 Market Share by Region, 2026 & 2036 (%)
9.6 Others (Academic Institutions, Research Organisations, Clinical Trial Centres)
9.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
9.6.2 Market Share by Region, 2026 & 2036 (%)

10 Antibody Drug Conjugates Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America Antibody Drug Conjugates Market Analysis
11.1 Key Findings
11.2 North America Antibody Drug Conjugates Market Attractiveness Index
11.3 North America Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
11.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Product
11.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
11.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
11.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
11.9 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
11.10 North America Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
11.11 U.S. Antibody Drug Conjugates Market Analysis
11.12 Canada Antibody Drug Conjugates Market Analysis

12 Europe Antibody Drug Conjugates Market Analysis
12.1 Key Findings
12.2 Europe Antibody Drug Conjugates Market Attractiveness Index
12.3 Europe Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
12.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Product
12.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
12.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
12.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
12.9 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
12.10 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
12.11 Germany Antibody Drug Conjugates Market Analysis
12.12 UK Antibody Drug Conjugates Market Analysis
12.13 France Antibody Drug Conjugates Market Analysis
12.14 Italy Antibody Drug Conjugates Market Analysis
12.15 Rest of Europe Antibody Drug Conjugates Market Analysis

13 Asia Pacific Antibody Drug Conjugates Market Analysis
13.1 Key Findings
13.2 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
13.3 Asia Pacific Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
13.5 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Product
13.6 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
13.7 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
13.8 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
13.9 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
13.10 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
13.11 Japan Antibody Drug Conjugates Market Analysis
13.12 China Antibody Drug Conjugates Market Analysis
13.13 India Antibody Drug Conjugates Market Analysis
13.14 Rest of Asia Pacific Antibody Drug Conjugates Market Analysis

14 Latin America Antibody Drug Conjugates Market Analysis
14.1 Key Findings
14.2 Latin America Antibody Drug Conjugates Market Attractiveness Index
14.3 Latin America Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
14.4 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
14.5 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Product
14.6 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
14.7 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
14.8 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
14.9 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
14.10 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
14.11 Brazil Antibody Drug Conjugates Market Analysis
14.12 Mexico Antibody Drug Conjugates Market Analysis
14.13 Rest of Latin America Antibody Drug Conjugates Market Analysis

15 MEA Antibody Drug Conjugates Market Analysis
15.1 Key Findings
15.2 MEA Antibody Drug Conjugates Market Attractiveness Index
15.3 MEA Antibody Drug Conjugates Market by Country, 2026, 2031 & 2036 (US$ Billion)
15.4 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Country
15.5 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Product
15.6 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
15.7 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
15.8 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
15.9 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
15.10 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by End-users
15.11 GCC Antibody Drug Conjugates Market Analysis
15.12 South Africa Antibody Drug Conjugates Market Analysis
15.13 Rest of MEA Antibody Drug Conjugates Market Analysis

16 Company Profiles
16.1 F. Hoffmann-La Roche Ltd
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Financial Analysis
16.1.3.1 Net Revenue, 2022-2025
16.1.3.2 R&D, 2022-2025
16.1.3.3 Business Segment Market Shares, 2025
16.1.4 Product Benchmarking
16.1.5 Strategic Outlook
16.2 Gilead Sciences, Inc.
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Financial Analysis
16.2.3.1 Net Revenue, 2022-2025
16.2.3.2 R&D, 2022-2025
16.2.3.3 Regional Market Shares, 2025
16.2.3.4 Business Segment Market Shares, 2025
16.2.4 Product Benchmarking
16.2.5 Strategic Outlook
16.3 Daiichi Sankyo Company, Limited
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Product Benchmarking
16.3.4 Strategic Outlook
16.4 AstraZeneca
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2022-2025
16.4.3.2 R&D, 2022-2025
16.4.3.3 Regional Market Shares, 2025
16.4.3.4 Business Segment Market Shares, 2025
16.4.4 Product Benchmarking
16.4.5 Strategic Outlook
16.5 Pfizer Inc.
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2022-2025
16.5.3.2 R&D, 2022-2025
16.5.3.3 Regional Market Shares, 2025
16.5.3.4 Business Segment Market Shares, 2025
16.5.4 Product Benchmarking
16.5.5 Strategic Outlook
16.6 Takeda Pharmaceutical Company Limited
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2022-2025
16.6.3.2 R&D, 2022-2025
16.6.3.3 Regional Market Shares, 2025
16.6.4 Product Benchmarking
16.6.5 Strategic Outlook
16.7 ADC Therapeutics SA
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2022-2025
16.7.3.2 R&D, 2022-2025
16.7.4 Product Benchmarking
16.7.5 Strategic Outlook
16.8 The Servier Laboratories
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Product Benchmarking
16.8.4 Strategic Outlook
16.9 BioNTech
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Financial Analysis
16.9.3.1 Net Revenue, 2022-2025
16.9.3.2 R&D, 2022-2025
16.9.4 Product Benchmarking
16.9.5 Strategic Outlook
16.10 Novartis AG
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2022-2025
16.10.3.2 R&D, 2022-2025
16.10.3.3 Regional Market Shares, 2025
16.10.3.4 Business Segment Market Shares, 2025
16.10.4 Product Benchmarking
16.10.5 Strategic Outlook
16.11 Johnson & Johnson
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2022-2025
16.11.3.2 R&D, 2022-2025
16.11.3.3 Regional Market Shares, 2025
16.11.3.4 Business Segment Market Shares, 2025
16.11.4 Product Benchmarking
16.12 BeOne Medicines
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Product Benchmarking
16.12.4 Strategic Outlook
16.13 Zymeworks Inc.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Product Benchmarking
16.13.4 Strategic Outlook
16.14 Innovent
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Product Benchmarking
16.14.4 Strategic Outlook
16.15 Astellas Pharma Inc.
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2022-2025
16.15.3.2 R&D, 2022-2025
16.15.3.3 Regional Market Shares, 2025
16.15.3.4 Business Segment Market Shares, 2025
16.15.4 Product Benchmarking
16.15.5 Strategic Outlook
16.16 AbbVie Inc.
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Financial Analysis
16.16.3.1 Net Revenue, 2022-2025
16.16.3.2 R&D, 2022-2025
16.16.3.3 Regional Market Shares, 2025
16.16.3.4 Business Segment Market Shares, 2025
16.16.4 Product Benchmarking
16.16.5 Strategic Outlook
16.17 GSK plc
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Financial Analysis
16.17.3.1 Net Revenue, 2022-2025
16.17.3.2 R&D, 2022-2025
16.17.3.3 Regional Market Shares, 2025
16.17.3.4 Business Segment Market Shares, 2025
16.17.4 Product Benchmarking
16.17.5 Strategic Outlook
16.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Product Benchmarking
16.18.4 Strategic Outlook
16.19 Duality Biologics
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Financial Analysis
16.19.3.1 Net Revenue, 2022-2025
16.19.4 Product Benchmarking
16.19.5 Strategic Outlook
16.20 Merck & Co., Inc.
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Financial Analysis
16.20.3.1 Net Revenue, 2022-2025
16.20.3.2 R&D, 2022-2025
16.20.3.3 Regional Market Shares, 2025
16.20.4 Product Benchmarking

17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

List of Tables
Table 1 Antibody Drug Conjugates Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Antibody Drug Conjugates in Phase III
Table 3 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): V-Shaped Recovery
Table 4 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): U-Shaped Recovery
Table 5 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): L-Shaped Recovery
Table 6 Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Kadcyla Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 8 Enhertu Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 9 Adcetris Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 10 Padcev Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 11 Trodelvy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 12 Polivy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 13 Other Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 14 Auristatins Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 15 Maytansinoids Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 16 Calicheamicin Derivatives Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 17 Topoisomerase I Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 18 Pyrrolobenzodiazepine (PBD) Dimers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 19 Other Payload Type Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 20 Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 22 Non-Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 23 Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 CD30 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 25 HER2 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 26 CD22 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 27 CD33 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 28 Other Target Antigens Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 29 Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 Blood Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 31 Breast Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 32 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 33 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 34 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 35 Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 36 Hospitals & Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 37 Speciality Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 38 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 39 Antibody Drug Conjugates Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 40 North America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 41 North America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 42 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 43 North America Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 44 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 45 North America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 46 North America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 47 U.S. Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 48 Canada Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 49 Europe Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 50 Europe Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 56 Germany Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 57 UK Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 58 France Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 59 Italy Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 60 Rest of Europe Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 61 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 62 Asia Pacific Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 63 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 64 Asia Pacific Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 65 Asia Pacific Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 68 Japan Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 69 India Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 70 India Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 71 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 72 Latin America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 73 Latin America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 74 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 75 Latin America Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 76 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 78 Latin America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 79 Brazil Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 80 Mexico Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 81 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 82 MEA Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 83 MEA Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 84 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 85 MEA Antibody Drug Conjugates Market Forecast by Technology, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 86 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 87 MEA Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 88 MEA Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 89 GCC Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 90 South Africa Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 91 Rest of MEA Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 92 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 94 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 95 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Gilead Sciences, Inc.: Product Benchmarking
Table 97 Gilead Sciences, Inc.: Strategic Outlook
Table 98 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
Table 100 DAIICHI SANKYO COMPANY, LIMITED: Strategic Outlook
Table 101 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 AstraZeneca: Product Benchmarking
Table 103 AstraZeneca: Strategic Outlook
Table 104 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Pfizer Inc.: Product Benchmarking
Table 106 Pfizer Inc.: Strategic Outlook
Table 107 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 109 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 110 ADC Therapeutics SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 ADC Therapeutics SA: Product Benchmarking
Table 112 ADC Therapeutics SA: Strategic Outlook
Table 113 The Servier Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 The Servier Laboratories: Product Benchmarking
Table 115 The Servier Laboratories: Strategic Outlook
Table 116 BioNTech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 BioNTech: Product Benchmarking
Table 118 BioNTech: Strategic Outlook
Table 119 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Novartis AG: Product Benchmarking
Table 121 Novartis AG: Strategic Outlook
Table 122 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Johnson & Johnson: Product Benchmarking
Table 124 BeOne Medicines: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 BeOne Medicines: Product Benchmarking
Table 126 BeOne Medicines: Strategic Outlook
Table 127 Zymeworks Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Zymeworks Inc.: Product Benchmarking
Table 129 Zymeworks Inc.: Strategic Outlook
Table 130 Innovent: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Innovent: Product Benchmarking
Table 132 Innovent: Strategic Outlook
Table 133 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Astellas Pharma Inc.: Product Benchmarking
Table 135 Astellas Pharma Inc.: Strategic Outlook
Table 136 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 AbbVie Inc.: Product Benchmarking
Table 138 AbbVie Inc.: Strategic Outlook
Table 139 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 GSK plc: Product Benchmarking
Table 141 GSK plc: Strategic Outlook
Table 142 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Product Benchmarking
Table 144 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: Strategic Outlook
Table 145 Duality Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Duality Biologics: Product Benchmarking
Table 147 Duality Biologics: Strategic Outlook
Table 148 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Merck & Co., Inc.: Product Benchmarking

List of Figures
Figure 1 Antibody Drug Conjugates Market Segmentation
Figure 2 Antibody Drug Conjugates Market: Research Methodology
Figure 3 Approved Antibody Drug Conjugates, Global Sales in US$, 2024 to 2036
Figure 4 Antibody Drug Conjugates Market: Research Methodology
Figure 5 Antibody Drug Conjugates Market by Product: Market Attractiveness Index
Figure 6 Antibody Drug Conjugates Market by Payload Type: Market Attractiveness Index
Figure 7 Antibody Drug Conjugates Market by Linker Type: Market Attractiveness Index
Figure 8 Antibody Drug Conjugates Market by Target Antigen: Market Attractiveness Index
Figure 9 Antibody Drug Conjugates Market by Applications: Market Attractiveness Index
Figure 10 Antibody Drug Conjugates Market by End-users: Market Attractiveness Index
Figure 11 Antibody Drug Conjugates Market Attractiveness Index by Region
Figure 12 Antibody Drug Conjugates Market: Market Dynamics
Figure 13 Antibody Drug Conjugates Market: Impact Analysis
Figure 14 Antibody Drug Conjugates Market: Generalized Process Flow for ADCs
Figure 15 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 16 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 17 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 18 Short Term & Long-Term Planning
Figure 19 Impact of U.S. and China Trade War
Figure 20 Most Impacted Countries
Figure 21 Antibody Drug Conjugates Market: Porter’s Five Forces Analysis
Figure 22 Antibody Drug Conjugates Market: PEST Analysis
Figure 23 Antibody Drug Conjugates Market Attractiveness Index by Product
Figure 24 Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
Figure 25 Antibody Drug Conjugates Market Share Forecast by Product, 2026, 2031, 2036 (%)
Figure 26 Kadcyla Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 27 Kadcyla Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Enhertu Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 29 Enhertu Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 Adcetris Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 31 Adcetris Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 32 Padcev Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 33 Padcev Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 34 Trodelvy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 35 Trodelvy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 36 Polivy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 37 Polivy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 38 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 39 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 40 Antibody Drug Conjugates Market Attractiveness Index by Payload Type
Figure 41 Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
Figure 42 Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026, 2031, 2036 (%)
Figure 43 Auristatins Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 44 Auristatins Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 45 Maytansinoids Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 46 Maytansinoids Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 47 Calicheamicin Derivatives Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 48 Calicheamicin Derivatives Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 49 Topoisomerase I Inhibitors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 50 Topoisomerase I Inhibitors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 51 Pyrrolobenzodiazepine (PBD) Dimers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 52 Pyrrolobenzodiazepine (PBD) Dimers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 53 Other Payload Type Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 54 Other Payload Type Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 55 Antibody Drug Conjugates Market Attractiveness Index by Linker Type
Figure 56 Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
Figure 57 Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026, 2031, 2036 (%)
Figure 58 Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 59 Cleavable Linkers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 60 Non-Cleavable Linkers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 61 Non-Cleavable Linkers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 62 Antibody Drug Conjugates Market Attractiveness Index by Target Antigen
Figure 63 Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
Figure 64 Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026, 2031, 2036 (%)
Figure 65 CD30 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 66 CD30 Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 67 HER2 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 68 HER2 Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 69 CD22 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 70 CD22 Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 71 CD33 Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 72 CD33 Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 73 Other Target Antigens Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 74 Other Target Antigens Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 75 Antibody Drug Conjugates Market Attractiveness Index by Applications
Figure 76 Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
Figure 77 Antibody Drug Conjugates Market Share Forecast by Applications, 2026, 2031, 2036 (%)
Figure 78 Blood Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 79 Blood Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 80 Breast Cancer Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 81 Breast Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 82 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 83 Autoimmune Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 84 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 85 Infectious Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 86 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 87 Other Applications Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 88 Antibody Drug Conjugates Market Attractiveness Index by End-users
Figure 89 Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 90 Antibody Drug Conjugates Market Share Forecast by End-users, 2026, 2031, 2036 (%)
Figure 91 Hospitals & Clinics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 92 Hospitals & Clinics Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 93 Speciality Centres Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 94 Speciality Centres Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 95 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 96 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 97 Antibody Drug Conjugates Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 98 Antibody Drug Conjugates Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 99 Antibody Drug Conjugates Market by Region, 2026-2036 (US$ Mn)
Figure 100 North America Antibody Drug Conjugates Market Attractiveness Index
Figure 101 North America Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 102 North America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 103 North America Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
Figure 104 North America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
Figure 105 North America Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
Figure 106 North America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
Figure 107 North America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
Figure 108 North America Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
Figure 109 North America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
Figure 110 North America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
Figure 111 North America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
Figure 112 North America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
Figure 113 North America Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
Figure 114 North America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 115 North America Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 116 U.S. Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 117 Canada Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 118 Europe Antibody Drug Conjugates Market Attractiveness Index
Figure 119 Europe Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 120 Europe Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 121 Europe Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
Figure 122 Europe Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
Figure 123 Europe Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
Figure 124 Europe Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
Figure 125 Europe Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
Figure 126 Europe Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
Figure 127 Europe Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
Figure 128 Europe Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
Figure 129 Europe Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
Figure 130 Europe Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
Figure 131 Europe Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
Figure 132 Europe Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 133 Europe Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 134 Germany Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 135 UK Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 136 France Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 137 Italy Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 138 Rest of Europe Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 139 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
Figure 140 Asia Pacific Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 141 Asia Pacific Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 142 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
Figure 143 Asia Pacific Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
Figure 144 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
Figure 145 Asia Pacific Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
Figure 146 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
Figure 147 Asia Pacific Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
Figure 148 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
Figure 149 Asia Pacific Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
Figure 150 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
Figure 151 Asia Pacific Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
Figure 152 Asia Pacific Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
Figure 153 Asia Pacific Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 154 Asia Pacific Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 155 Japan Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 156 China Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 157 India Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 158 Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 159 Latin America Antibody Drug Conjugates Market Attractiveness Index
Figure 160 Latin America Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 161 Latin America Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 162 Latin America Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
Figure 163 Latin America Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
Figure 164 Latin America Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
Figure 165 Latin America Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
Figure 166 Latin America Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
Figure 167 Latin America Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
Figure 168 Latin America Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
Figure 169 Latin America Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
Figure 170 Latin America Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
Figure 171 Latin America Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
Figure 172 Latin America Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
Figure 173 Latin America Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 174 Latin America Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 175 Brazil Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 176 Mexico Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 177 Rest of Latin America Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 178 MEA Antibody Drug Conjugates Market Attractiveness Index
Figure 179 MEA Antibody Drug Conjugates Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 180 MEA Antibody Drug Conjugates Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 181 MEA Antibody Drug Conjugates Market Share Forecast by Country, 2026 & 2036 (%)
Figure 182 MEA Antibody Drug Conjugates Market Forecast by Product, 2026-2036 (US$ Billion, AGR %)
Figure 183 MEA Antibody Drug Conjugates Market Share Forecast by Product, 2026 & 2036 (%)
Figure 184 MEA Antibody Drug Conjugates Market Forecast by Payload Type, 2026-2036 (US$ Billion, AGR %)
Figure 185 MEA Antibody Drug Conjugates Market Share Forecast by Payload Type, 2026 & 2036 (%)
Figure 186 MEA Antibody Drug Conjugates Market Forecast by Linker Type, 2026-2036 (US$ Billion, AGR %)
Figure 187 MEA Antibody Drug Conjugates Market Share Forecast by Linker Type, 2026 & 2036 (%)
Figure 188 MEA Antibody Drug Conjugates Market Forecast by Target Antigen, 2026-2036 (US$ Billion, AGR %)
Figure 189 MEA Antibody Drug Conjugates Market Share Forecast by Target Antigen, 2026 & 2036 (%)
Figure 190 MEA Antibody Drug Conjugates Market Forecast by Applications, 2026-2036 (US$ Billion, AGR %)
Figure 191 MEA Antibody Drug Conjugates Market Share Forecast by Applications, 2026 & 2036 (%)
Figure 192 MEA Antibody Drug Conjugates Market Forecast by End-users, 2026-2036 (US$ Billion, AGR %)
Figure 193 MEA Antibody Drug Conjugates Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 194 GCC Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 195 South Africa Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 196 Rest of MEA Antibody Drug Conjugates Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 197 F. Hoffmann-La Roche Ltd: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 198 F. Hoffmann-La Roche Ltd: R&D, 2022-2025 (US$ Million, AGR %)
Figure 199 F. Hoffmann-La Roche Ltd: Business Segment Market Shares (%), 2025
Figure 200 Gilead Sciences, Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 201 Gilead Sciences, Inc.: R&D, 2022-2025 (US$ Million, AGR %)
Figure 202 Gilead Sciences, Inc.: Regional Market Shares (%), 2025
Figure 203 Gilead Sciences, Inc.: Business Segment Market Shares (%), 2025
Figure 204 AstraZeneca: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 205 AstraZeneca: R&D, 2022-2025 (US$ Million, AGR %)
Figure 206 AstraZeneca: Regional Market Shares (%), 2025
Figure 207 AstraZeneca: Business Segment Market Shares (%), 2025
Figure 208 Pfizer Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 209 Pfizer Inc.: R&D, 2022-2025 (US$ Million, AGR %)
Figure 210 Pfizer Inc.: Regional Market Shares (%), 2025
Figure 211 Pfizer Inc.: Business Segment Market Shares (%), 2025
Figure 212 Takeda Pharmaceutical Company Limited: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 213 Takeda Pharmaceutical Company Limited: R&D, 2022-2025 (US$ Million, AGR %)
Figure 214 Takeda Pharmaceutical Company Limited: Regional Market Shares (%), 2025
Figure 215 ADC Therapeutics SA: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 216 ADC Therapeutics SA: R&D, 2022-2025 (US$ Million, AGR %)
Figure 217 BioNTech: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 218 BioNTech: R&D, 2022-2025 (US$ Million, AGR %)
Figure 219 Novartis AG: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 220 Novartis AG: R&D, 2022-2025 (US$ Million, AGR %)
Figure 221 Novartis AG: Regional Market Shares (%), 2025
Figure 222 Novartis AG: Business Segment Market Shares (%), 2025
Figure 223 Johnson & Johnson: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 224 Johnson & Johnson: R&D, 2022-2025 (US$ Million, AGR %)
Figure 225 Johnson & Johnson: Regional Market Shares (%), 2025
Figure 226 Johnson & Johnson: Business Segment Market Shares (%), 2025
Figure 227 Astellas Pharma Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 228 Astellas Pharma Inc.: R&D, 2022-2025 (US$ Million, AGR %)
Figure 229 Astellas Pharma, Inc.: Regional Market Shares (%), 2025
Figure 230 Astellas Pharma Inc.: Business Segment Market Shares (%), 2025
Figure 231 AbbVie Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 232 AbbVie Inc.: R&D, 2022-2025 (US$ Million, AGR %)
Figure 233 AbbVie, Inc.: Regional Market Shares (%), 2025
Figure 234 AbbVie Inc.: Business Segment Market Shares (%), 2025
Figure 235 GSK plc: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 236 GSK plc: R&D, 2022-2025 (US$ Million, AGR %)
Figure 237 GSK plc: Regional Market Shares (%), 2025
Figure 238 GSK plc: Business Segment Market Shares (%), 2025
Figure 239 Duality Biologics: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 240 Merck & Co., Inc.: Net Revenue, 2022-2025 (US$ Million, AGR %)
Figure 241 Merck & Co., Inc.: R&D, 2022-2025 (US$ Million, AGR %)
Figure 242 Merck & Co., Inc.: Regional Market Shares (%), 2025

List of Companies Profiled in the Report
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
Daiichi Sankyo Company, Limited
AstraZeneca
Pfizer Inc.
Takeda Pharmaceutical Company Limited
ADC Therapeutics SA
The Servier Laboratories
BioNTech
Novartis AG
Johnson & Johnson
BeOne Medicines
Zymeworks Inc.
Innovent
Astellas Pharma Inc.
AbbVie Inc.
GSK plc
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Duality Biologics
Merck & Co., Inc.

List of Other Companies Mentioned in the Report
Alnylam
Araris Biotech
Bio-Thera Solutions
Day One Biopharmaceuticals, Inc.
Debiopharm
Edgewise Therapeutics Inc.
FUJIFILM Corporation
Gilead Sciences
MilliporeSigma
Myricx Bio
ONCOMATRYX
Simtra Biopharma Solutions
Taiho Oncology
Taiho Pharmaceutical
VALANX Biotech
Xilio Therapeutics, Inc.
Xinda Biopharmaceutical Group

List of Associations Mentioned in the Report
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
China National Medical Products Administration (NMPA)
European Medicines Agency (EMA)
European Society for Medical Oncology (ESMO)
Japan Pharmaceuticals and Medical Devices Agency (PMDA)
National Cancer Institute (NCI)
National Comprehensive Cancer Network (NCCN)
UK Medicines and Healthcare products Regulatory Agency (MHRA)
U.S. Food and Drug Administration (FDA)